AMERICAN ASSOCIATION for CANCER RESEARCH Conclusio
Post# of 144499
![](/assets/46931549/no_avatar_available_thumb.jpg)
We observed that treatment with Leronlimab resulted in RAPID DECREASES in the presence of multiple populations of TACS in 75% of (26) Patients, which also SIGNIFICANTLY correlated with Better PFS and OS after 1-year analysis. Oh...Where Oh... Where is the FDA?
![Like This Post](/images/thumb-up.png)
![Dislike This Post](/images/thumb-down.png)